INTRODUCTION
Immune checkpoints are inhibitory pathways used by the immune system to protect host tissues from damage, particularly when the immune system is activated. Recently, these mechanisms have been found to be functionally relevant in cancers for evasion of immunemediated rejection (1, 2) . On the basis of this, immune checkpoint blockade has been demonstrated to be a promising approach for cancer therapy.
Cytotoxic T lymphocyte antigen 4 (CTLA4; CD152) is a transmembrane protein expressed on regulatory T cells (T regs ) and activated CD4 + and CD8 + T cells (3) . It functions as an inducer of immunosuppressive signals by binding to CD80 or CD86 on antigen-presenting cells. Thus, CTLA4 blocking antibodies (Abs) (aCTLA4) can potentiate the activation of effector T cells. In addition, anti-mouse CTLA4 Ab clone 9H10, but not UC-4F10-11 (4F10), depletes T regs through Abdependent cell-mediated cytotoxicity, further enhancing its antitumor effects (4, 5) . In the clinic, aCTLA4 (ipilimumab) treatment resulted in improved survival of melanoma patients (6) .
Some tumor cells express programmed death ligand 1 (PD-L1) (CD274 and B7-H1), a key molecule in the pathway to evade immune response via binding to programmed cell death-1 (PD-1) on activated T cells (7) (8) (9) . The PD-L1/PD-1 interaction results in decreased cytokine production, inhibition of proliferation, and apoptosis of T cells. Both anti-PD-1 (aPD-1; pidilizumab, pembrolizumab, and nivolumab) and anti-PD-L1 (aPD-L1; atezolizumab and avelumab) blocking Abs have inhibited tumor growth in mouse models and in the clinic (10) (11) (12) .
Because the CTLA4 and PD-1/PD-L1 inhibitory pathways are nonredundant, the combination of aPD-L1 and aCTLA4 can have synergistic antitumor effects (13) . Clinical trials using both nivolumab and ipilimumab showed a prolongation of survival, and these drugs have been approved for melanoma treatment by the U.S. Food and Drug Administration. However, 68.7% of patients showed grade 3 or 4 side effects. In particular, 36.4% of these patients could not continue with the therapy due to treatment-related adverse events (14) .
Heparin-binding domains (HBDs) in several GFs bind to the HBDs derived from a variety of extracellular matrix (ECM) proteins (15) (16) (17) (18) (19) . By screening the binding of GFs to a variety of ECM proteins, we have discovered that the HBD of placenta growth factor-2 (PlGF-2 123-144 ) has an exceptionally high affinity for multiple ECM proteins (20) . We have shown that fusion of the PlGF-2 123-144 domain to GFs enhanced their tissue retention and therapeutic efficacy in mouse models of skin and bone regeneration (20) . Here, we engineered immune checkpoint blockade Abs conjugated with PlGF-2 123-144 peptide for cancer immunotherapy. We hypothesized that the enhanced retention of checkpoint blockade Abs in tissue surrounding the tumor would improve their antitumor efficacy by enhancing T cell activation and decrease the side effects of therapy by lowering systemic exposure after local administration.
RESULTS

PlGF-2 123-144 peptide-conjugated Abs bind to ECM proteins and their targets
We first examined the capacity of PlGF-2 123-144 -conjugated Abs to bind ECM proteins in vitro. After mixing immunoglobulin G (IgG) Abs with sulfosuccinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC), the PlGF-2 123-144 peptide was cross-linked covalently to the Ab (Fig. 1A) . SDS-polyacrylamide gel electrophoresis (PAGE) revealed that molecular weights of both light and heavy chains of IgG were increased (Fig. 1B ). An average of 6.3 and 6 PlGF-2 123-144 peptides were bound to monoclonal aCTLA4 (4F10) and monoclonal aPD-L1, respectively, as calculated by matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry (MS; fig. S1 ). PlGF-2 123-144 conjugation did not yield high-molecular Fig. 1E and fig. S4 ). PlGF-2 123-144 -aCTLA4 and PlGF-2 123-144 -aPD-L1 also recognized their target antigens with similar K d values to the unmodified Abs ( Fig. 1E and fig. S5 ). Together, these data showed that PlGF-2 123-144 -Abs bind ECM proteins without impairment of their antigen recognition capacities. S8 ). We next performed histological analysis to determine whether PlGF-2 123-144 -Abs remain at the injection site long term after peritumoral injection through binding to endogenous ECM molecules in vivo. Both PlGF-2 123-144 -aCTLA4 and PlGF-2 123-144 -aPD-L1 were detected within the tumor tissue 6 days after injection. In comparison, both unmodified aCTLA4 and unmodified aPD-L1 were not detected at this time point ( fig. S9 ). Together, PlGF-2 123-144 conjugation enhanced tumor tissue retention of both aCTLA4 and aPD-L1 when injected peritumorally.
PlGF-2 123-144 conjugation decreases treatment-related adverse events Because PlGF-2 123-144 -Abs displayed prolonged retention near the injection site, we hypothesized that the concentrations of Abs in plasma would be lower compared to unmodified Abs. To test this hypothesis, we measured the Ab concentrations in blood plasma over time (Fig. 2, A and B). After inoculation with B16F10 cells, mice were given a single administration (100 mg each) of aCTLA4 and aPD-L1 on day 4. Concentrations were highest in all groups on the first day after injection. Furthermore, injection of unmodified Abs via peritumoral and intraperitoneal administration routes showed similar blood plasma concentrations. The concentrations of both PlGF-2 123-144 -Abs in blood plasma were lower compared to their unmodified forms and were barely detected 3 days after injection, suggesting that PlGF-2 123-144 conjugation may reduce systemic toxicity of aCTLA4/aPD-L1. Neither unmodified aPD-L1 nor PlGF-2 123-144 -aPD-L1 (rat IgG2b) bound to mFcRn with high affinity, confirming that PlGF-2 123-144 conjugation did not affect Ab recycling (fig. S10). Next, side effects were examined. aCTLA4 and aPD-L1 were administered 4 and 7 days after tumor inoculation, and then serum cytokine concentrations and the liver damage marker alanine aminotransferase (ALT) were examined. Unmodified Ab administration increased both tumor necrosis factor-a (TNFa) and interferon-g (IFN-g) concentrations in serum, whereas PlGF-2 123-144 -Abs did not (Fig. 2, C and D) . In addition, unmodified Ab, but not PlGF-2 123-144 -Ab treatment, increased ALT activity in the serum (Fig. 2E) . Histologic analysis showed that unmodified Abs induced marked morphological changes and lymphocyte infiltration in the liver (Fig. 2F and fig. S11 ), whereas tissue structure was relatively maintained after PlGF-2 123-144 -Ab treatment. To further evaluate the reduced systemic toxicity achieved by PlGF-2 123-144 conjugation, we used nonobese diabetic (NOD) male mice, which develop spontaneous diabetes in low frequency but develop autoimmune diabetes after aPD-L1 administration via aPD-L1 binding to islet cells (21) . Unmodified aPD-L1 administration induced diabetes in all eight of the 16-weekold NOD male mice by day 6, whereas diabetes incidence with PlGF-2 123-144 -aPD-L1 was 0% on 25 days (Fig. 2G) Fig. 3A and fig. S12A ). Administration of aCTLA4 + aPD-L1 + PlGF-2 123-144 peptide (without conjugation) did not produce an antitumor effect, indicating that the conjugation of PlGF-2 123-144 to Abs is indispensable for this action. We repeated administration of both Abs using mice inoculated with wild-type (WT) B16F10 cells lacking the OVA transgene. PlGF-2 123-144 -combination Abs again slowed tumor progression and extended survival, whereas unmodified Abs did not (Fig. 3B and fig. S12B ). Higher doses (100 mg each per injection) of PlGF-2 123-144 -Abs using aCTLA4 clone 9H10, which induces T reg depletion (5), further suppressed tumor growth and extended survival (Fig. 3C and fig. S12C ). Even a single peritumoral injection of PlGF-2 123-144 -combination Abs at a later time point, 7 days after inoculation, with a larger starting tumor volume of 90 mm 3 , resulted in smaller tumor size (Fig. 3D and fig. S12D ). Further increasing the dose (300 mg each, twice, and then 100 mg each, twice) again slowed tumor growth in the PlGF-2 123-144 -Ab-treated group (Fig. 3E and fig. S12E ). All single-agent treatments with PlGF-2 123-144 -aCTLA4 or unmodified aCTLA4 or aPD-L1 exhibited similar growth curves as phosphatebuffered saline (PBS) treatment controls ( fig. S13 ), suggesting that the combination of PlGF-2 123-144 -aCTLA4 and PlGF-2 123-144 -aPD-L1 administration is crucial under these conditions. The PlGF-2 123-144 peptide did not affect tumor growth in vitro, suggesting that the PlGF-2 123-144 peptide itself had little effect on tumor growth ( fig. S14 ). Together, these data indicate that local treatment with PlGF-2 123-144 -aCTLA4 + PlGF-2 123-144 -aPD-L1 mediates robust antitumor effects compared to their unmodified forms. PlGF-2 123-144 -Abs and PBS were injected peritumorally (pt), and unmodified Abs were injected either intraperitoneally (ip) or peritumorally. Blood plasma was collected on days 5, 7, 9, and 11. Concentrations of (A) aCTLA4 and (B) PD-L1 in blood plasma were determined by ELISA [PBS, n = 6; Abs (intraperitoneally), n = 5; others, n = 8; mean ± SEM]. (C to F) PlGF-2 123-144 -aCTLA4 or unmodified aCTLA4 and aPD-L1 (500 mg each per injection) were injected peritumorally on days 4 and 7. On day 9, blood serum was collected, and concentrations of (C) TNFa and (D) IFN-g and (E) ALT activity in serum were measured (mean ± SEM). (F) Histologic liver sections were obtained on day 8. The number of lymphocytic infiltration spots was counted and divided by area (mean ± SEM). (G) Sixteen-week-old male NOD mice were given 100 mg of PlGF-2 123-144 -aPD-L1 or unmodified aPD-L1 on days 0 and 2 and evaluated for the development of diabetes. All Ab injections were intradermal at the back skin. Clinical diabetes was defined as blood glucose concentrations of 250 mg/dl for three consecutive days. Statistical analyses were done using ANOVA with Tukey's test. Kruskal-Wallis test followed by Dunn's multiple comparison was used in (C) due to nonparametric data. Log-rank (Mantel-Cox) test was performed for diabetes-free survival curves. Two experimental repeats. *P < 0.05, **P < 0.01. N.S., not significant. D). PlGF-2 123-144 -combination Abs also increased the number of CD4 + T cells in the tumor (Fig. 4 , E and F). The percentage of effector CD4 + T cells was increased as well ( Fig. 4G ) (22, 23) . The percentage of CD25 + Foxp3 + T regs in the CD4 + T cell population was maintained (Fig. 4H) .
To test whether tumor-infiltrating CD8 + T cells produced more effector cytokines and higher levels of cytotoxicity, CD8 + T cells were extracted and stimulated ex vivo using aCD3 and aCD28 (13 ) were inoculated on day 0. PlGF-2 123-144 -aCTLA4 + PlGF-2 123-144 -aPD-L1 (PlGF-2 123-144 -Abs), aCTLA4 + aPD-L1 (Abs), Abs + non-cross-linked PlGF-2 123-144 peptide, or PBS was administered (A and B) 25 mg on days 4, 7, and 10; (C) 100 mg on days 4, 7, and 10; (D) 100 mg on day 7; or (E) 300 mg on days 4 and 6, and 100 mg on days 9 and 12. Abs were injected either intraperitoneally or peritumorally. Ab doses per administration are indicated in the figure. aCTLA4 clones 4F10 (A and B) and 9H10 (C to E) were used. Graphs depict tumor volume until the first mouse died. Tumor volumes are presented as means ± SEM. (A) PBS (peritumorally), n = 10; Abs (peritumorally), n = 8; Abs (intraperitoneally), n = 7; PlGF-2 123-144 -Abs (peritumorally), n = 12; Abs + PlGF-2 123-144 (peritumorally), n = 8. (B) Abs (peritumorally), n = 7; other treatment groups, n = 9. (C) n = 10. (D) PlGF-2 123-144 -Abs (peritumorally), n = 8; other treatment groups, n = 7. (E) Abs (intraperitoneally), n = 6; PlGF-2 123-144 -Abs (peritumorally), n = 8; other treatment groups, n = 7. Three experimental repeats. Statistical analyses were done using ANOVA with Tukey's test. *P < 0.05, **P < 0.01. ANOVA with Tukey's test. Kruskal-Wallis test followed by Dunn's multiple comparison was used in (E), (F), and (P) due to nonparametric data. *P < 0.05, **P < 0.01.
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PlGF-2 123-144 -Ab treatment induces systemic antitumor immunity The increase of systemic central memory and PD-1 + CD8 + T cells, as well as stimuli-responsive cytokine-producing CD8 + T cells in the tumor after PlGF-2 123-144 -aCTLA4 + PlGF-2 123-144 -aPD-L1 treatment, led us to investigate whether PlGF-2 123-144 -Abs could mediate antitumor responses in a distant tumor. B16F10 cells were inoculated in the left back of the mouse on day 0 and in the right back of the mouse on day 2 (Fig. 5A) . Subsequently, the Abs were injected peritumorally beside the left tumor or intraperitoneally on days 4, 7, and 10. The peritumoral injection of PlGF-2 123-144 -combination Abs slowed the outgrowth of both the left (ipsilateral) and right (contralateral) tumors (Fig. 5, B and C, and fig. S17 ). In contrast, unmodified Abs had little therapeutic effect on either tumor when injected peritumorally or intraperitoneally. These data indicate that PlGF-2 123-144 -aCTLA4 + PlGF-2 123-144 -aPD-L1 treatment near one tumor enhances a systemic antitumor immunological activity. (Fig. 6A) . We similarly investigated the MMTV-PyMT (mouse mammary tumor virus-polyomavirus middle T antigen) model of breast cancer (25) and found that peritumoral administration of the PlGF-2 123-144 -combination Abs also suppressed tumor growth and prolonged survival in these mice (Fig. 6, B and C) . PlGF-2 123-144 -combination Ab administration induced eradication of tumors in 11 of 16 mice, whereas combination treatment with unmodified Abs eradicated tumors in 5 of 15 mice. To assess long-term anticancer immune protection, mice whose tumors were eradicated by PlGF-2 123-144 -combination Ab treatment were rechallenged with MMTV-PyMT cells. Only one of these nine mice developed palpable tumors, whereas all naïve mice grew detectable tumors, suggesting that PlGF-2 123-144 -combination Abs induced immunologic memory (Fig. 6D) . These data indicate that the PlGF-2 123-144 -aCTLA4 + PlGF-2 123-144 -aPD-L1 therapeutic effect is applicable to multiple cancer types.
PlGF
-2 123-144 -Ab treatment has therapeutic effects on genetically engineered mouse models of melanoma and breast cancer To extend our results beyond transplantable tumor models, we used Tyr:Cretumor growth compared to PBS-treated or unmodified Ab-treated groups
DISCUSSION
Recently, aCTLA4 and aPD-1/aPD-L1 monoclonal Abs have been recognized as highly promising drugs for cancer treatment, exhibiting therapeutic effects on various types of cancer (12, (26) (27) (28) . Although their therapeutic effects in the clinic are remarkable, treatment-related adverse events are serious problems (14, 29, 30) . Here, the incidence of such adverse events due to checkpoint blockade was reduced by PlGF-2 123-144 conjugation with peritumoral administration. PlGF-2 123-144 -Abs, which remain localized near the tumor tissue injection site and thus reduce the concentration in the blood circulation, may maintain the systemic immune homeostasis by avoiding influence on non-tumor antigen-specific T cells. In the NOD mouse model, we showed that PlGF-2 123-144 conjugation reduces the risk of PD-L1/PD-1 inhibitioninduced autoimmune diabetes, which has been reported in the clinic (31) (32) (33) . We assume that the reason why none of the NOD mice developed diabetes during 25 days after PlGF-2 123-144 -aPD-L1 injections is that PlGF-2 123-144 -aPD-L1 is barely detected in the blood plasma 3 days after injections. PlGF-2 123-144 conjugation may even allow decreases in the administered dose because we observed tumor growth delay at low dosages, where unmodified Abs had no effect. These data are encouraging with regard to treatment of patients who have discontinued checkpoint blockade therapy due to adverse events, as well as those who are not amenable to systemic chemotherapy. Local immune therapy has been reported to have equivalent antitumor efficacy to systemic administration of therapeutics through efficient activation of immune systems (34) (35) (36) (37) (38) (39) . Recently, intratumoral administration of cytokines, adjuvants, genes, dendritic cells, and immunomodulatory Abs has been tested in the clinic (40) . Regarding checkpoint blockade, clinical trials have been performed with intratumoral injection of aCTLA4 (ipilimumab) in melanoma, colorectal cancer, and lymphoma (40) . Intratumoral injection with the combination of ipilimumab and IL-2 generated responses in both injected and noninjected lesions in the majority of patients in a phase 1 clinical trial (41) . In a mouse model, local administration of aCTLA4 with slow-release formulations (such as Montanide oil emulsion or polymer microparticles) enabled the use of lower doses of Ab while maintaining antitumor efficacy (34, 36, 37) . In our study, we have developed a molecular engineering approach to provide for local checkpoint blockade and enable injection site retention without biomaterial carriers, which resulted in enhanced antitumor efficacy and reduced adverse events compared to local injection of the unmodified forms of checkpoint blockade. Because PlGF-2 123-144 -Abs promiscuously bind to ECM proteins, as shown above, their enhanced antitumor efficacy should be primarily observed when they are injected locally. (A) PBS (peritumorally), n = 9; Abs (peritumorally), n = 11; PlGF-2 123-144 -Abs (peritumorally), n = 12. (B and C) PBS (peritumorally), n = 13; Abs (peritumorally), n = 15; PlGF-2 123-144 -Abs (peritumorally), n = 16. (D) Naïve, n = 7; survivors, n = 9. Three experimental repeats. Statistical analyses were done using ANOVA with Tukey's test. Kruskal-Wallis test followed by Dunn's multiple comparison was used in (B) due to nonparametric data. For single comparisons, a two-tailed Student's t test was used. Log-rank (Mantel-Cox) test for survival curves. *P < 0.05, **P < 0.01. As for the MMTV-PyMT breast cancer model, PlGF-2 123-144 -combination Abs eradicated cancers in 69% of mice compared to 33% in the unmodified Ab-treated controls. These data suggest that PlGF-2 123-144 -aCTLA4 + PlGF-2 123-144 -aPD-L1 effectively suppresses growth of multiple cancer types, but complete remission is dependent on the type of cancer.
Growth of B16F10 and
Our localized therapy also suppressed growth of a tumor contralateral to the injection site, which is consistent with earlier observations of induction of systemic immunity (35, 36, 38, 39) . These data suggest that it may be feasible to treat patients with oligometastatic tumors by PlGF-2 123-144 -aCTLA4 + PlGF-2 123-144 -aPD-L1 treatment. With the low concentration of PlGF-2 123-144 -conjugated Abs in the blood combined with the increase in activated CD8 + T cells, the mechanism of distant tumor treatment is likely due to effective tumor antigen-specific CD8 + T cell activation, which is disseminated systemically. Unmodified Abs distributed systemically via intraperitoneal or peritumoral administration did not suppress B16F10 tumor growth at the doses used in this study. + T cells play a crucial role in antitumor immune responses (13, 43, 45) , that may explain why peritumoral injection of PlGF-2 123-144 -aCTLA4 + PlGF-2 123-144 -aPD-L1, but not unmodified Abs, suppressed tumor outgrowth in both ipsilateral and contralateral tumors.
By design, PlGF-2 123-144 -IgG binds to a variety of ECM proteins, which should contribute to prolonged tissue retention at the injection site, as we have previously seen in PlGF-2 123-144 -fused GFs (20) . Bound PlGF-2 123-144 -Abs can be released by plasmin. Because cancer cells secrete more proteases than normal cells (46, 47) , cancer-derived proteases may contribute to PlGF-2 123-144 -Ab release from ECM in vivo.
We used two aCTLA4 clones (9H10 and 4F10) to investigate whether T reg depletion contributes to antitumor efficacy. Because both clones suppressed tumor growth in their PlGF-2 123-144 -conjugated forms, it appears that aCTLA4 primarily contributed to the antitumor activity through its effect of ligand blocking rather than T reg depletion.
From the point of view of clinical translation, a major advantage of PlGF-2 123-144 -checkpoint blockade is material availability. Checkpoint blockade Abs are already used in the clinic, and PlGF-2 123-144 peptide, which is derived from the human sequence, is short enough to be chemically synthesized on a large scale with nonbiological origin. Moreover, synthesizing PlGF-2 123-144 -Abs is simple. Reactions can be performed under aqueous conditions in only 90 min, using chemistry that is analogous to PEGylation of proteins. These features may help PlGF-2 123-144 -checkpoint blockade to overcome the barriers to clinical translation. A limitation of synthesizing PlGF-2 123-144 -Abs is the inability to control the site of peptide conjugation. However, we have shown that PlGF-2 123-144 conjugation did not alter the Ab-antigen affinities. The same reaction is also used to make antibody-drug conjugates, such as trastuzumab emtansine (48) .
In conclusion, we found that the antitumor activity of aCTLA4 and aPD-L1 was enhanced by the addition of ECM-binding properties. 
MATERIALS AND METHODS
Study design
This study was designed to test the antitumor efficacy and adverse effects of matrix-binding checkpoint blockade Abs against melanoma and breast cancer with local injection compared to conventional checkpoint blockade. We tested whether the local activation of antitumor immune response after matrix-binding checkpoint blockade Ab treatment would suppress the growth of a distant tumor. These experiments were designed to develop therapeutic strategies to improve the conventional form of checkpoint blockade in the clinic. Statistical methods were not used to predetermine necessary sample size, but sample sizes were chosen on the basis of estimates from pilot experiments and previously published results such that appropriate statistical tests could yield significant results. Synthesis of PlGF-2 123-144 -Ab and tumor treatments were performed by multiple individuals to ensure reproducibility. All experiments were replicated at least twice. For animal studies, mice were randomized into treatment groups within a cage immediately before the first Ab injection, and all mice were treated the same way. Tumor growth was determined by direct measurement of the tumors. The survival endpoint was reached when the tumor size reached more than 500 mm 3 for B16F10 melanoma and MMTV-PyMT breast cancer and more than 1000 mm 3 for Tyr:Cre-ER
/Pten fl/fl melanoma. The n values used to calculate statistics are indicated in the figure legends. Samples were not excluded from analysis. Experiments were not performed in a blinded fashion except for counting liver-infiltrating lymphocytes. Statistical methods are described in the "Statistical analysis" section. Original data are located in table S1.
Synthesis of PlGF-2 123-144 -Abs
Rat anti-mouse PD-L1 (clone 10F.9G2, Bio X Cell), hamster anti-mouse CTLA4 (clone UC10-4F10-11 or 9H10, Bio X Cell), or rat IgG2a control Ab (BioLegend) was incubated with 15 equiv. of sulfo-SMCC for 30 min at room temperature. Excess sulfo-SMCC was removed using a Zeba spin desalting column (Thermo Fisher Scientific). Fifteen equivalents of the PlGF-2 123-144 peptide (RRRPKGRGKRRREKQRPTDCHL) was then added and reacted for 1 hour at 4°C. Endotoxin concentration was checked by QUANTI-Blue assay (Invivogen) using HEK-Blue mTLR4 cells (Invivogen), not to exceed 0.1 endotoxin unit per mouse injection limit. The peptide was synthesized with >95% purity by GenScript.
SDS-polyacrylamide gel electrophoresis SDS-PAGE was performed on 4 to 20% gradient gels (Bio-Rad) after Abs were reduced with 10 mM dithiothreitol. After electrophoresis, gels were stained with SimplyBlue SafeStain (Thermo Fisher Scientific) according to the manufacturer's instruction. Gel images were acquired with the ChemiDoc XRS+ system (Bio-Rad).
Matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry MALDI-TOF MS analyses were done by the proteomics core facility at the Ecole Polytechnique Fédérale de Lausanne (EPFL). Ab solutions were dialyzed to exchange the buffer to 50 mM ammonium bicarbonate. The Ab samples (5 to 10 mg) were desalted with a C4 filter pipette tip (custom-made 250-mg capacity) and then eluted using 85% acetonitrile, 0.1% trifluoroacetic acid in water. The cleaned Abs were dried in SpeedVac for 10 min and resolubilized in 5 ml of 2% acetonitrile, 0.1% trifluoroacetic acid in water. Analyses by MALDI-TOF were conducted on an Applied Biosystems 4800 MALDI TOF/TOF mass spectrometer using high mass linear positive mode. Typically, spectra from 1000 to 1500 laser shots were summed to obtain the final spectrum. MALDI Matrix 2,5-dihydroxybenzoic acid (Applied Biosystems) at 70 mg/ml in methanol was used for all experiments. Analyte (0.5 ml) and matrix solution (1 ml) were deposited on the stainless steel target, mixed with a micropipette, and allowed to air-dry, forming a cocrystalline sample/matrix complex. The measurements were externally calibrated at three points with a mix of carbonic anhydrase, enolase, and BSA (Sigma-Aldrich).
Nanoparticle tracking analysis
Particle concentration in the unmodified or PlGF-2 123-144 -Ab solution was analyzed with a NanoSight NS300 (Malvern Instruments), equipped with a low volume flow cell gasket and a 532-nm green laser module. The Ab solution was injected manually in the sample chamber with syringes until the solution reached the tip of the nozzle and then infused at a constant flow rate using a syringe pump for measurements. All measurements were performed at room temperature. The software used for capturing and analyzing the data was the NTA 3.2 Dev Build 3.2.16. The samples were measured for 60 s. One thousand four hundred ninety-eight frames were analyzed in each analysis.
Detection of Ab binding to ECM proteins
Ninety-six-well ELISA plates (Greiner Bio-One) were coated with recombinant human ECM proteins (10 mg/ml), fibronectin (SigmaAldrich), fibrinogen (von Willebrand factor-and fibronectin-depleted; Enzyme Research Laboratories), osteopontin (Sigma-Aldrich), vitronectin (Sigma-Aldrich), collagen I (EMD Millipore), collagen II (EMD Millipore), collagen III (EMD Millipore), or collagen IV (EMD Millipore) in PBS for 1 hour at 37°C, followed by blocking with 2% BSA in PBS with 0.05% Tween 20 (PBS-T) for 1 hour at room temperature. Then, wells were washed with PBS-T and further incubated with PlGF-2 123-144 -Abs or unmodified Abs (10 mg/ml each) for 1 hour at room temperature. After three washes with PBS-T, wells were incubated for 1 hour at room temperature with horseradish peroxidase (HRP)-conjugated Abs against rat IgG or hamster IgG (Jackson ImmunoResearch). After washes, bound Abs were detected with tetramethylbenzidine substrate by measurement of the absorbance at 450 nm with subtraction of the absorbance at 570 nm.
Binding affinity assay Ninety-six-well ELISA plates (Greiner Bio-One) were coated with fibronectin, collagen I, rmCTLA4 (Sino Biological), or rmPD-L1 (Sino Biological) (10 mg/ml each; in PBS) for 1 hour at 37°C, followed by blocking with 2% BSA in PBS-T for 1 hour at room temperature. Then, wells were washed with PBS-T and further incubated with PlGF-2 or unmodified Abs at increasing concentrations for 1 hour at room temperature. After three washes with PBS-T, wells were incubated for 1 hour at room temperature with HRP-conjugated Abs against hamster IgG or rat IgG. After washes, bound Abs were detected with tetramethylbenzidine substrate by measurement of the absorbance at 450 nm with subtraction of the absorbance at 570 nm. The apparent K d values were obtained by nonlinear regression analysis in Prism software (version 7, GraphPad Software) assuming one-site-specific binding.
Inhibition of PlGF-2 123-144 -Ab binding to fibronectin by heparin Ninety-six-well ELISA plates were coated with fibronectin (10 mg/ml) in PBS for 1 hour at 37°C and further blocked with 2% BSA in PBS-T for 1 hour at room temperature. Then, wells were washed with PBS-T and incubated with PlGF-2 123-144 -conjugated rat IgG2a control Ab (10 mg/ml; in PBS-T with 0.1% BSA) with increasing concentrations of heparin for 1 hour at room temperature. After three washes with PBS-T, bound Abs were detected using HRP-conjugated goat anti-rat secondary Ab (Jackson ImmunoResearch).
PlGF-2 123-144 cleavage by plasmin PlGF-2 123-144 -Abs (1 mg/ml) were incubated with plasmin (0.1 U/ml) overnight at 37°C. Cleavage of PlGF-2 123-144 by plasmin was detected by SDS-PAGE. ECM-binding affinity of plasmin-treated Ab was determined by ELISA as described above.
Release profiles of PlGF-2 123-144 -aPD-L1 and aPD-L1 from collagen gels Collagen gels were prepared by mixing 8.5 ml of bovine collagen (5 mg/ml; Symatese) with 800 ml of 10× MEM (Life Technologies) followed by 1.8 ml of NaOH (0.1 M). Five hundred microliters of neutralized collagen solution was allowed to gel in 1.5-ml protein lowbinding tubes (Thermo Fisher Scientific). After 15 min of gelation, PlGF-2 123-144 -aPD-L1 or aPD-L1 (10 mg/ml) was incubated for 3 hours in 800 ml of release buffer (0.1% BSA in PBS), followed by wash with release buffer. Thereafter, 800 ml of release buffer was added to each collagen gel and incubated at 37°C (5% CO 2 ). Every 24 hours, release buffer aliquots were taken and frozen down, followed by the addition of new release buffer to the collagen gels. These release buffer steps were repeated five times. After the fifth buffer change, the collagen gels were incubated with plasmin for 12 hours (0.1 U/ml; Roche). To get the release profile of the Abs from collagen gel, all the collected release samples were thawed, and the concentrations were obtained by ELISA as described above.
Mice and cell lines C57BL/6 and FVB mice, ages 8 to 12 weeks, were obtained from Charles River, unless otherwise noted. NOD mice were obtained from The Jackson Laboratory and bred in the animal facility at the University of Chicago. Tyr:Cre-ER + /LSL-Braf V600E /Pten f l/f l mice, ages 6 to 12 weeks, were 
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Abs retention analysis and immunohistochemistry of skin tissue sections
The backs of C57BL/6 mice were shaved. A total of 5 × 10 5 B16F10 cells resuspended in 50 ml of PBS were injected intradermally on the left side of the back of each mouse. After 4 days, mice were injected with 10 mg of aCTLA4 (4F10) and aPD-L1 (peritumorally). Histological analysis was performed on serial sections (10-mm frozen sections) until reaching the central portion of the melanoma. Cryosections, fixed with 4% paraformaldehyde (PFA) and blocked with 2% BSA, were incubated with Alexa Fluor 488-conjugated anti-hamster or anti-rat Ab (both from Jackson ImmunoResearch) and biotinylated anti-S100 Ab (Invitrogen) for 1 hour at room temperature, followed by staining with Alexa Fluor 647-conjugated streptavidin (BioLegend). Images were taken with DMi8 microscope (Leica).
Ab concentration analysis B16F10 melanoma cells (5 × 10 5 ) were injected intradermally on the left side of the back of each mouse. After 4 days, mice were injected with 100 mg of aCTLA4 (9H10) or 100 mg of aPD-L1 (peritumorally or intraperitoneally). Blood samples were collected in heparinized tubes 5, 7, 9, and 11 days after tumor inoculation. Concentrations of aCTLA4 and aPD-L1 in plasma were measured by ELISA as described above.
Detection of Ab binding to rmFcRn
Ninety-six-well ELISA plates (Greiner Bio-One) were coated with rmFcRn (1 mg/ml; R&D Systems) in PBS at 37°C overnight, followed by blocking with 2% BSA in PBS-T (pH 7.4) for 1 hour at room temperature. Then, wells were washed with PBS-T (pH 7.4) and further incubated with PlGF-2 123-144 -aPD-L1 or unmodified aPD-L1, or human normal IgG (R&D Systems) at increasing concentrations in PBS (pH 6.0 or pH 7.4) for 1 hour at room temperature. After three washes with PBS-T (pH 6.0 or pH 7.4), wells were incubated for 1 hour at room temperature with HRP-conjugated Abs against rat IgG or human IgG in PBS (pH 6.0 or pH 7.4). After three washes with PBS-T (pH 6.0 or pH 7.4), bound Abs were detected with tetramethylbenzidine substrate by measurement of the absorbance at 450 nm and subtracting the absorbance at 570 nm.
Serum cytokine concentration analysis B16F10 melanoma cells (5 × 10 5 ) were injected intradermally on the left side of the back of each 12-week-old C57BL/6 mouse (The Jackson Laboratory). After 4 and 7 days, mice received two doses of 500 mg of aCTLA4 and aPD-L1 peritumorally. On day 9, blood samples were collected in tubes, followed by overnight incubation at 4°C. Cytokine concentrations in serum were measured by Ready-SET-Go! ELISA kits for mouse TNFa and mouse IFN-g (eBioscience) and mouse IL-2 DuoSet ELISA kit (R&D Systems) according to the manufacturer's protocol.
ALT assays B16F10 melanoma cells (5 × 10 5 ) were injected intradermally on the left side of the back of each 12-week-old C57BL/6 mouse (The Jackson Laboratory). After 4 and 7 days, mice received two doses of 500 mg of aCTLA4 and aPD-L1. On day 9, blood samples were collected in tubes, followed by >4-hour incubation at 4°C. ALT activity in serum was measured by ALT Assay Kit (Sigma-Aldrich) according to the manufacturer's protocol.
Histology B16F10 melanoma cells (5 × 10 5 ) were injected intradermally on the left side of the back of each 12-week-old C57BL/6 mouse (The Jackson Laboratory). After 4 and 7 days, mice were given two doses of 500 mg of aCTLA4 and aPD-L1. Eight and 10 days after tumor inoculation, livers were collected and fixed with 4% PFA. After embedding in paraffin, blocks were cut into 5-mm sections, followed by staining with hematoxylin and eosin. Images were captured with an EVOS FL Auto microscope (Life Technologies). The number of spots of infiltrated lymphocytes was counted by an investigator blinded to the treatment group.
Diabetes monitoring of NOD mice after aPD-L1 treatment Sixteen-week-old male NOD mice were given 100 mg of aPD-L1 on days 0 and 2. All Ab injections were intradermal in the back skin. Clinical diabetes was defined as a blood glucose concentration of 250 mg/dl for three consecutive days. Blood glucose was measured by AlphaTRAK 2 Glucose Meter (Abbott Animal Health). Blood glucose concentrations were monitored daily from 2 days after initiation of the treatment until 25 days after the initiation of Ab treatment.
B16F10 tumor inoculation and Ab injection
A total of 1 × 10 6 B16F10-OVA or 5 × 10 5 B16F10 cells resuspended in 50 ml of PBS were inoculated intradermally on the left side of the back of each C57BL/6 mouse. After 4 (when all tumors were visible and tumor size were around 20 mm 3 ), 7, or 10 days, mice were injected with 25, 50, 100, or 300 mg of aCTLA4 and/or aPD-L1 intradermally beside the tumor peritumorally or intraperitoneally For distant tumor experiments, 5 × 10 5 B16F10 cells were injected intradermally on the left side of the back of each mouse on day 0 and on the right side on day 2. On days 4, 7, and 10, mice were injected with 100 mg of aCTLA4 and aPD-L1 (peritumorally or intraperitoneally). Tumors were measured with a digital caliper starting 4 days after the first tumor inoculation, and volumes were calculated as ellipsoids, where V = 4/3 × 3.14 × depth/2 × width/2 × height/2. Mice were sacrificed when either tumor volume had reached over 500 mm 3 .
Cell proliferation assay B16F10 melanoma cells were plated in 24-well plates at a density of 5 × 10 4 cells per well and incubated overnight at 37°C in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). The PlGF-2 123-144 peptide (1, 10, and 100 mg/ml) was then added. After 3 days of incubation, cell numbers were counted using a hemocytometer.
Tissue and cell preparation and T cell subset analysis B16F10 melanoma cells (5 × 10 5 ) were injected intradermally on the left side of the back of each C57BL/6 mouse. After 4 and 7 days, mice were injected with 100 mg of aCTLA4 and aPD-L1 (peritumorally or intraperitoneally). Mice were sacrificed on day 8. Spleens, LNs, and tumors
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were harvested. Tumors were digested in DMEM supplemented with 2% FBS, collagenase D (2 mg/ml), and deoxyribonuclease I (40 mg/ml; Roche) for 30 min at 37°C. Single-cell suspensions were obtained by gently disrupting the organs through a 70-mm cell strainer. Red blood cells were lysed with ACK lysing buffer (Quality Biological). Cells were counted and resuspended in Iscove's modified Dulbecco's medium supplemented with 10% FBS and 1% penicillin/streptomycin (full medium; all from Life Technologies) and used for flow cytometry staining and ex vivo T cell stimulation.
Flow cytometry and Abs
Single-cell suspensions from spleens, LNs, and tumors were prepared as described above. After a washing step, about 2 × 10 6 cells were used for Ab staining. Abs against the following molecules were used throughout the paper if not otherwise indicated: CD3 (145-2C11, BD Biosciences), CD4 (RM4-5, BD Biosciences), CD8a (53-6.7, BD Biosciences), CD25 (PC61, BD Biosciences), CD45 (30-F11, BD Biosciences), CD44 (IM7, BD Biosciences), CD62L (MEL-14, BD Biosciences), PD-1 (29F.1A12, BioLegend), Foxp3 (MF23, BD Biosciences), IL-2 (JES6-5H4, BD Biosciences), IFN-g (XMG1.2, BD Biosciences), TNFa (MP6-XT22, eBioscience), and Gzmb (NGZB, eBioscience). Fixable live/dead cell discrimination was performed using Fixable Viability Dye eFluor 455 (eBioscience) according to the manufacturer's instructions. Staining was carried out on ice for 20 min if not indicated otherwise, and intracellular staining was performed using the Foxp3 staining kit according to the manufacturer's instructions (BioLegend). Staining of OVA-specific cells was performed using the SIINFEKL-MHCI pentamer (ProImmune), conjugated with phycoerythrin. For staining, pentamers were diluted 1:10 in PBS containing 2% FBS and incubated for 20 min at room temperature. After a washing step, cells were stained with specific Abs for 20 min on ice before fixation. All flow cytometric analyses were done using a Fortessa flow cytometer (BD Biosciences) and analyzed using FlowJo software (Tree Star).
Ex vivo T cell stimulation
Single-cell suspensions from tumor were prepared as described above. CD8 + T cells were isolated using EasySep kits (STEMCELL Technologies) following the manufacturer's instructions, except that biotinylated aCD105 (12403, BioLegend) was added to the EasySep CD8 + T Cell Isolation Cocktail to remove B16-F10 melanoma cells. Ninety-six-well cell culture plates (BD Falcon) were coated with aCD3 (10 mg/ml; 145-2C11, BioLegend) in PBS overnight at 37°C. Extracted T cells from tumor were plated in 96-well plates and cultured in full medium for 6 hours at 37°C in the presence of aCD28 (2 mg/ml; EL-4, BioLegend) and brefeldin A (5 mg/ml; Sigma-Aldrich). Cells were harvested, stained, and analyzed by flow cytometry as described above. /Pten f l/f l mice were shaved on the back, and 5 ml of 4-OH-tamoxifen (Sigma-Aldrich) at 10 mg/ml was applied topically, as previously described (24) . Zero, 3, and 6 days after visible tumor development, mice were injected with 100 mg each of aCTLA4 and aPD-L1 peritumorally for a total of three injections. Volume was computed as Volume = Surface × Z, where Surface is computed through ImageJ analysis and Z is the thickness of the tumor, measured with a digital caliper. Mice were sacrificed when tumor volume had reached more than 1000 mm 3 .
MMTV-PyMT tumor inoculation and Ab injection
The hair surrounding the mammary glands of FVB mice was shaved. A total of 8 × 10 5 MMTV-PyMT cells resuspended in 50 ml of PBS were injected subcutaneously into the mammary gland on the right side of each mouse. After 7, 10, or 13 days, mice were injected with 100 mg each of aCTLA4 and aPD-L1 (peritumorally). Tumors were measured with a digital caliper as described above. Mice were sacrificed when tumor volume reached more than 500 mm 3 .
Statistical analysis
Statistical significance of differences between experimental groups was calculated with Prism software (version 7, GraphPad). For parametric data, variance between groups was found to be similar by BrownForsythe test, and one-way ANOVA followed by Tukey's honestly significant different post hoc test was used for statistical analysis. For nonparametric data, Kruskal-Wallis test followed by Dunn's multiple comparison test was used. For single comparisons, a two-tailed Student's t test was used. Survival curves were analyzed by using the log-rank (Mantel-Cox) test. The n values used to calculate statistics are indicated in figure legends. All experiments were replicated at least twice. The symbols * and ** indicate P values less than 0.05 and 0.01, respectively.
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